Opthea Ltd

Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.

OPT | US

Overview

Corporate Details

ISIN(s):: US68386J2087
LEI:
Country:: United States of America
Address:: LEVEL 4, 3141 SOUTH YARRA
Website:: https://opthea.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Opthea Ltd. is a clinical-stage biopharmaceutical company that was focused on developing novel therapies for vision-threatening retinal diseases. The company's primary development program centered on its lead candidate, sozinibercept (OPT-302), a first-in-class biologic inhibitor of VEGF-C and VEGF-D. Sozinibercept was being evaluated in combination with standard-of-care anti-VEGF-A therapies for the treatment of wet age-related macular degeneration (wet AMD), with the goal of delivering superior visual outcomes. However, in March 2025, the company announced that its pivotal Phase 3 clinical trials (COAST and ShORe) did not meet their primary endpoints, leading to the discontinuation of the development program and significant corporate restructuring.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Opthea Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Opthea Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Opthea Ltd via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL
HYUNDAI BIOLAND Co.,Ltd. Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.	South Korea	052260
Icure Pharmaceutical Incorporation Develops transdermal patches for dementia/Parkinson's and offers cosmetic ODM/OBM services.	South Korea	175250
Idorsia Ltd Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.	Switzerland	IDIA
IGC Pharma, Inc. Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.	United States of America	IGC
IL DONG PHARMACEUTICAL CO., LTD. Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.	South Korea	249420
ILSUNG IS CO., LTD. Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.	South Korea	003120